BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho CT, Chang YJ, Yang LX, Wei PL, Liu TZ, Liu JJ. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells. PLoS One 2015;10:e0136340. [PMID: 26355599 DOI: 10.1371/journal.pone.0136340] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ong MS, Deng S, Halim CE, Cai W, Tan TZ, Huang RY, Sethi G, Hooi SC, Kumar AP, Yap CT. Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers (Basel) 2020;12:E238. [PMID: 31963677 DOI: 10.3390/cancers12010238] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
2 Ko P, Choi JH, Song S, Keum S, Jeong J, Hwang YE, Kim JW, Rhee S. Microtubule Acetylation Controls MDA-MB-231 Breast Cancer Cell Invasion through the Modulation of Endoplasmic Reticulum Stress. Int J Mol Sci 2021;22:6018. [PMID: 34199510 DOI: 10.3390/ijms22116018] [Reference Citation Analysis]
3 Sivakumar G. Upstream biomanufacturing of pharmaceutical colchicine. Critical Reviews in Biotechnology 2017;38:83-92. [DOI: 10.1080/07388551.2017.1312269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
4 Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Sci Rep 2021;11:2074. [PMID: 33483574 DOI: 10.1038/s41598-021-81577-x] [Reference Citation Analysis]
5 Posey KL, Coustry F, Veerisetty AC, Hossain MG, Gambello MJ, Hecht JT. Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies. Am J Pathol 2019;189:132-46. [PMID: 30553437 DOI: 10.1016/j.ajpath.2018.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kumar A, Sharma PR, Mondhe DM. Potential anticancer role of colchicine-based derivatives: an overview. Anticancer Drugs 2017;28:250-62. [PMID: 28030380 DOI: 10.1097/CAD.0000000000000464] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
7 Park M, Hwang JW, Cho Y, Kim S, Han SH, Yu J, Ha S, Kim WY, Kim SN, Kim IS, Kim YK. A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells. Sci Rep 2021;11:10822. [PMID: 34031528 DOI: 10.1038/s41598-021-90337-w] [Reference Citation Analysis]
8 Shchegravina ES, Maleev AA, Ignatov SK, Gracheva IA, Stein A, Schmalz H, Gavryushin AE, Zubareva AA, Svirshchevskaya EV, Fedorov AY. Synthesis and biological evaluation of novel non-racemic indole-containing allocolchicinoids. European Journal of Medicinal Chemistry 2017;141:51-60. [DOI: 10.1016/j.ejmech.2017.09.055] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
9 Kim SJ, Jegal KH, Im JH, Park G, Kim S, Jeong HG, Cho IJ, Kang KW. Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer. Cancer Chemother Pharmacol 2020;85:685-97. [PMID: 32157413 DOI: 10.1007/s00280-020-04043-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Florent R, Poulain L, N'Diaye M. Drug Repositioning of the α1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug? Int J Mol Sci 2020;21:E5339. [PMID: 32727149 DOI: 10.3390/ijms21155339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A. p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncoimmunology 2017;6:e1264564. [PMID: 28197392 DOI: 10.1080/2162402X.2016.1264564] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]